Hiperplasia Prostática Benigna e PSA: o efeito dominó
DOI:
https://doi.org/10.5712/rbmfc7(25)654Palavras-chave:
Hiperplasia Prostática, Antígeno Prostático Específico, Medição de RiscoResumo
Após a publicação de uma recomendação contra o rastreio câncer prostático pela U.S. Preventive Services Task Force, a comunidade médica não poderá desvincular-se das particularidades relacionadas com o antígeno prostático específico (PSA). O enfoque dado às guidelines da Hiperplasia Prostática surge pela possível partilha, a determinado ponto da sua abordagem, de um trilho que cursa também com a solicitação do PSA. Os resultados de dois grandes ensaios clínicos constituem o maior corpo da evidência actual e deles sobressai que o número de homens que evitaram a morte por câncer prostático após submetidos ao rastreio foi reduzido. Há evidência de que 100-200 em 1000 homens rastreados terão um falso-positivo, a maioria dos quais será biopsada, com possíveis danos psicológicos e orgânicos. O Médico de Família deverá relembrar que não é recomendado que se ofereça esta análise, sem que primeiro discuta, juntamente com o paciente, as questões inerentes ao PSA.
Downloads
Métricas
Referências
Croswell JM, Kramer BS, Crawford D. Screening for Prostate Cancer with PSA testing: current status and future directions. Oncology. 2011; 25(6): 1-14.
Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2012; 157(2): 120 34. PMid:22801674. DOI: https://doi.org/10.7326/0003-4819-157-2-201207170-00459
Brett T. Prostate specific antigen. Aust Fam Phys. 2011; 40(7):497-500.
Caroll P, Albertsen PC, Greene K, Babaian RJ, Carter HB, Gann PH et al. Prostate-Specific Antigen Best Practice Statement: 2009 Update. American Urological Association Education and Research; 2009. p. 1-32.
U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force Recommendation statement. Ann Intern Med. 2008; 149:185-91. PMid: 18678845. DOI: https://doi.org/10.7326/0003-4819-149-3-200808050-00008
Andriole GL, Crawford ED, Grubb R, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012; 104:125-32. PMid: 22228146. http://dx.doi.org/10.1093/jnci/djr500 DOI: https://doi.org/10.1093/jnci/djr500
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of follow-up. N Eng J Med. 2012; 366:981-90. PMid: 22417251. http://dx.doi.org/10.1056/NEJMoa1113135 DOI: https://doi.org/10.1056/NEJMoa1113135
Carlsson S, Vickers AJ, Roobol M, Eastham J, Scardino P, Lilja H, et al. Prostate Cancer Screening: Facts, Statistics and Interpretation in Response to the US Preventive Services Task Force Review. J Clin Oncol. 2012; 21 (30): 2581-84. PMid:22711853. http://dx.doi.org/10.1200/JCO.2011.40.4327 DOI: https://doi.org/10.1200/JCO.2011.40.4327
Bull M, Schröder FH. Screening for prostate cancer - the controversy continues, but can it be resolved?. Acta Oncol. 2011;50 (suppl 1):4-11. PMid: 21604934. http://dx.doi.org/10.3109/0284186X.2010.522197 DOI: https://doi.org/10.3109/0284186X.2010.522197
Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol. 201; 60(1): 106-17. DOI: https://doi.org/10.1016/j.eururo.2011.03.055
Sausville J, Naslund M. Benign prostatic hyperplasia and prostate cancer: an overview for primary care physicians. Int J Clin Pract. 2010; 64(13): 1740-45. PMid: 21070524. http://dx.doi.org/10.1111/j.1742-1241.2010.02534.x DOI: https://doi.org/10.1111/j.1742-1241.2010.02534.x
Oelke M, Bachmann A, Emberton M, Gravas S, Michel MC, N’Dow J, et al. Guidelines on the management of Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology; 2012. DOI: https://doi.org/10.1016/j.eururo.2013.03.004
Brown CT, O’Flynn E, Meulen JVD, Newman S, Mundy AR, Emberton M. The fear of prostate cancer in men with lower urinary tract symptoms: should symptomatic men be screened? BJU International. 2003; 91: 30-2. PMid: 12614245. http://dx.doi.org/10.1046/j.1464-410X.2003.04013.x DOI: https://doi.org/10.1046/j.1464-410X.2003.04013.x
AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia. Diagnosis and treatment recommendations. J Urol. 2003; 70:530-47. DOI: https://doi.org/10.1097/01.ju.0000078083.38675.79
Clinical Practice Guidelines. The management of uncomplicated lower urinary tract symptoms in men. National Health and Medical Research Council; 2000.
Cavalcanti AGLC, Errico G, Araújo JFC, Ribeiro JGA, Scaletscky R. Directrizes em Urologia Hiperplasia Prostática Benigna. Sociedade Brasileira de Urologia; 2004.
Novara G, Galfano A, Gardi M, Ficarra V, Boccon-Gibod L, Artibani W. Critical Review of Guidelines for BPH Diagnosis and Treatment Strategy. Eur Urol Suppl. 2005; suppl 6: 418-29. DOI: https://doi.org/10.1016/j.eursup.2006.02.005
Heidenreich A, Bolla M, Joniau S, Mason MD, Matveev V, Mottet N, et al. Guidelines on Prostate Cancer. European Association of Urology; 2010. p. 12-14.
Direcção Geral de Saúde. Prescrição e determinação do antigénio específico da próstata - PSA. Direcção Geral de Saúde; 2011. p. 1-12.
Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010; 102:605-13. PMid: 20413742. http://dx.doi.org/10.1093/jnci/djq099 DOI: https://doi.org/10.1093/jnci/djq099
Silva FC. Rastreio do cancro da próstata. Acta Urol. 2005; 22(3): 11 13.
Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B et al. Screening for prostate cancer: Systematic review and meta-analysis of randomised controlled trials. BMJ. 2010; 341:c4543. PMid: 20843937 PMCid:2939952. http://dx.doi.org/10.1136/bmj.c4543 DOI: https://doi.org/10.1136/bmj.c4543
Ilic D, O’Connor D, Green S, Wilt TJ. Screening for prostate cancer: An updated Cochrane systematic review. BJU Int. 2011; 107:882-891. PMid: 21392207. http://dx.doi.org/10.1111/j.1464-410X.2010.10032.x DOI: https://doi.org/10.1111/j.1464-410X.2010.10032.x
Barratt AL, Stockler MR. Screening for prostate cancer: explaning new trial results and their implications to patients. MJA. 2009; 191:226-229. PMid: 19705986. DOI: https://doi.org/10.5694/j.1326-5377.2009.tb02760.x
Bastos J, Botelho F, Pina F, Lunet N. Evolução da mortalidade por cancro da próstata em Portugal (1980 - 2006). Acta Med Port. 2011; 24:499-504. PMid: 22521005.
Tornblom M, Eriksson H, Franzen S, Gustafsson O, Lilja H, Norming U, et al. Lead time associated with screening for prostate cancer. Int J Cancer. 2004;108:122-9. PMid: 14618626. http://dx.doi.org/10.1002/ijc.11554 DOI: https://doi.org/10.1002/ijc.11554
Kim SP, Karnes RJ. An Editorial Response to the USPSTF Prostate cancer screening: the case for patient-centered shared decision-making. J Men’s Health. 2012; 1(9):5-8. http://dx.doi.org/10.1016/j.jomh.2011.12.002 DOI: https://doi.org/10.1016/j.jomh.2011.12.002
Sheridan SL, Harris RP, Woolf SH. Shared Decision Making About Screening and Chemoprevention: a suggested approach from the U.S. Preventive Services Task Force. Am J Prev Med. 2004; 26(1):56-66. PMid: 14700714. http://dx.doi.org/10.1016/j.amepre.2003.09.011 DOI: https://doi.org/10.1016/j.amepre.2003.09.011
Frydenberg M. Diagnosing prostate cancer What GPs need to know. Aust Fam Phys. 2007; 36(5): 345-47.
Martin RM, Vatten L, Gunnell D, Romundstad PI, Nilsen TIL. Lower urinary tract symptoms and risk of prostate cancer: The HUNT 2 Cohort, Norway. Int J Cancer. 2008; 123:1924-28. PMid: 18661522. http://dx.doi.org/10.1002/ijc.23713 DOI: https://doi.org/10.1002/ijc.23713
Matsubara A, Yasumoto H, Teishima J, Seki M, Mita K, Hasegawa Y, et al. Lower urinary tract symptoms and risk of prostate cancer in Japanese men. Int J Urol. 2006; 13(8):1098-102. PMid: 16903936. http://dx.doi.org/10.1111/j.1442-2042.2006.01504.x DOI: https://doi.org/10.1111/j.1442-2042.2006.01504.x
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Ao submeterem um manuscrito à RBMFC, os autores mantêm a titularidade dos direitos autorais sobre o artigo, e autorizam a RBMFC a publicar esse manuscrito sob a licença Creative Commons Atribuição 4.0 e identificar-se como veículo de sua publicação original.
